Tactile Systems Technology (TCMD) Hisse Özeti
Bir tıbbi teknoloji şirketi olan Tactile Systems Technology, Inc. Amerika Birleşik Devletleri'nde yetersiz hizmet alan kronik hastalıkları tedavi etmek için tıbbi cihazlar geliştirmekte ve sağlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 3/6 |
| Geçmiş Performans | 4/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
TCMD Community Fair Values
Create NarrativeSee what 22 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tactile Systems Technology, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$30.28 |
| 52 Haftanın En Yüksek Seviyesi | US$37.77 |
| 52 Haftanın En Düşük Seviyesi | US$9.42 |
| Beta | 0.83 |
| 1 Aylık Değişim | 20.78% |
| 3 Aylık Değişim | 14.98% |
| 1 Yıllık Değişim | 192.84% |
| 3 Yıllık Değişim | 21.46% |
| 5 Yıllık Değişim | -40.86% |
| Halka arzdan bu yana değişim | 173.29% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 25
TCMD: Connected Care Rollout And Buybacks Will Support Future Upside
Analysts have raised their price target on Tactile Systems Technology by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a slightly higher valuation framework. What's in the News Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, aimed at chronic neuromuscular and respiratory conditions across pediatric and geriatric patients, with updates focused on comfort, ease of use, and connected care features.Anlatı Güncellemesi • Jun 07
TCMD: Connected Care Launch And Governance Changes Will Support Continued Upside
Analysts have nudged their price target on Tactile Systems Technology to $39.50 from $38, reflecting updated views on fair value, discount rate, revenue growth, profit margin assumptions, and expected future P/E, as highlighted in recent Street research. What's in the News Tactile Systems Technology announced the full commercial launch of its next generation AffloVest high frequency chest wall oscillation therapy system, designed to support long term adherence for chronic neuromuscular and respiratory conditions across pediatric and geriatric patients.Anlatı Güncellemesi • Apr 23
TCMD: Lymphedema Execution And Multi Year Guidance Will Support Continued Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to around $38, supported by higher projections for revenue growth, improved profit margins, and a lower assumed future P/E multiple following recent Q4 upside and updated multi year guidance. Analyst Commentary Recent Street research on Tactile Systems Technology highlights a range of views on execution, growth prospects, and valuation following the Q4 results and updated multi year guidance.Recent updates
Anlatı Güncellemesi • Jun 25
TCMD: Connected Care Rollout And Buybacks Will Support Future Upside
Analysts have raised their price target on Tactile Systems Technology by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a slightly higher valuation framework. What's in the News Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, aimed at chronic neuromuscular and respiratory conditions across pediatric and geriatric patients, with updates focused on comfort, ease of use, and connected care features.Anlatı Güncellemesi • Jun 07
TCMD: Connected Care Launch And Governance Changes Will Support Continued Upside
Analysts have nudged their price target on Tactile Systems Technology to $39.50 from $38, reflecting updated views on fair value, discount rate, revenue growth, profit margin assumptions, and expected future P/E, as highlighted in recent Street research. What's in the News Tactile Systems Technology announced the full commercial launch of its next generation AffloVest high frequency chest wall oscillation therapy system, designed to support long term adherence for chronic neuromuscular and respiratory conditions across pediatric and geriatric patients.Anlatı Güncellemesi • Apr 23
TCMD: Lymphedema Execution And Multi Year Guidance Will Support Continued Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to around $38, supported by higher projections for revenue growth, improved profit margins, and a lower assumed future P/E multiple following recent Q4 upside and updated multi year guidance. Analyst Commentary Recent Street research on Tactile Systems Technology highlights a range of views on execution, growth prospects, and valuation following the Q4 results and updated multi year guidance.Analiz Makalesi • Apr 18
Should You Think About Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD) Now?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), might not be a large cap stock, but it received a lot of attention...Anlatı Güncellemesi • Apr 08
TCMD: Lymphedema Momentum And Q4 Execution Will Drive Multi Year Upside
The updated analyst price target for Tactile Systems Technology has been set at $38. This reflects analysts' reactions to recent Q4 outperformance, higher long-term estimates, and ongoing attention to productivity, patient referrals, and the lymphedema business.Anlatı Güncellemesi • Mar 25
TCMD: Lymphedema Momentum And Q4 Execution Will Support Multi Year Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to $38, reflecting a series of Street target increases into the $32 to $42 range, supported by recent Q4 outperformance, updated multi year guidance, and progress in productivity and cost controls. Analyst Commentary Street commentary around Tactile Systems Technology is mixed, with several bullish analysts lifting targets on the back of Q4 execution and longer term guidance, while more cautious voices question how much upside remains after the post earnings re rating.Anlatı Güncellemesi • Mar 09
TCMD: Lymphedema Momentum And Q4 Execution Will Support Ongoing Upside Potential
Analysts have nudged their average price target for Tactile Systems Technology to $38. This reflects stronger recent Q4 execution, raised long term estimates and ongoing improvements in productivity, patient referrals and cost controls.Anlatı Güncellemesi • Feb 23
TCMD: Lymphedema Momentum And Q4 Execution Will Support Measured Turnaround Expectations
The analyst fair value estimate for Tactile Systems Technology has been raised from $29.75 to $38.00, reflecting higher Street price targets in the $32 to $42 range as analysts cite recent Q4 upside, improved productivity and cost controls, and ongoing strength in the lymphedema business. Analyst Commentary Street research on Tactile Systems Technology is generally constructive, with higher fair value assumptions linked to recent Q4 performance, execution on productivity and cost controls, and expectations around the lymphedema business.Anlatı Güncellemesi • Feb 08
TCMD: Index Inclusion And Stable Outlook Will Shape Measured Turnaround Expectations
Analysts have maintained their fair value estimate for Tactile Systems Technology at $29.75 per share. They cited only very small adjustments to assumptions regarding the discount rate, revenue growth, profit margins, and future P/E multiples, rather than any change in the core outlook.Anlatı Güncellemesi • Jan 25
TCMD: Turnaround Momentum And Buyback Will Test Q3 Outperformance Sustainability
Analysts have raised their price targets on Tactile Systems Technology to a roughly mid to high $20s to low $30s range, citing stronger than expected Q3 results, improved productivity, sales force expansion, new products, and better reimbursement trends that together support a higher fair value assessment. Analyst Commentary Recent research points to a more constructive view on Tactile Systems Technology following its Q3 outperformance, with several firms raising price targets and upgrading ratings based on execution and perceived upside to fair value.Anlatı Güncellemesi • Jan 10
TCMD: Q3 Turnaround Momentum And Buyback Will Face Execution Risk
Analysts have raised their price target on Tactile Systems Technology to about $29.75 from $24, citing stronger recent earnings performance, expectations for operational improvements, and support for a higher future P/E multiple. Analyst Commentary Recent research updates on Tactile Systems Technology highlight a clear shift toward a more constructive stance, with multiple firms lifting price targets after Q3 results and pointing to both execution progress and valuation support.Analiz Makalesi • Dec 18
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 28% gain in the...Anlatı Güncellemesi • Dec 17
TCMD: Q3 Outperformance And Buyback Will Mask Limited Upside Ahead
Analysts have raised their price target on Tactile Systems Technology by about $8.50 to roughly $32 per share, citing significant Q3 outperformance, improving productivity and reimbursement trends, and expectations for a return to double digit growth by 2026. Analyst Commentary Recent research updates reflect a notably more constructive stance on Tactile Systems Technology, with bullish analysts pointing to operational momentum, clearer reimbursement visibility, and a sizable underpenetrated patient pool as key drivers of potential upside in the shares.Anlatı Güncellemesi • Dec 03
TCMD: Q3 Outperformance And Buyback Plan Will Shape Turnaround Outlook
Analysts have raised their price expectations for Tactile Systems Technology toward the low to mid $30 range, citing a massive Q3 outperformance, consistent estimate beats, and growing confidence in a 2026 growth reacceleration and higher sustainable earnings power. Analyst Commentary Recent Street research reflects a broadly constructive stance on Tactile Systems Technology following its strong Q3 performance and improving fundamentals.Anlatı Güncellemesi • Nov 19
TCMD: Sustained Product Execution And Buyback Plan Set To Shape Outlook
Analysts have raised their price target on Tactile Systems Technology significantly, from approximately $16.83 to $24.00. They cite strong quarterly outperformance and growing confidence in the company’s turnaround and future growth prospects.Analiz Makalesi • Nov 06
Results: Tactile Systems Technology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) investors will be delighted, with the company turning in some strong...Anlatı Güncellemesi • Nov 03
TCMD: Market Leadership And Coverage Momentum Will Drive Expansion Into Underserved Patients
Narrative Update on Tactile Systems Technology Analysts have reaffirmed their price target for Tactile Systems Technology at $16.83 per share. They cite the company's leadership in key market segments and anticipated growth acceleration as a result of recent strategic improvements.Anlatı Güncellemesi • Oct 20
At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have maintained their price target for Tactile Systems Technology at $23.50. They cite the company's leading positions in key device markets and an improved outlook following recent strategic adjustments.Anlatı Güncellemesi • Oct 05
At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have raised their fair value estimate for Tactile Systems Technology from $13.50 to $16.83 per share. The change is attributed to optimism about the company's strengthened market leadership and the potential for renewed growth following recent strategic improvements.Analiz Makalesi • Oct 04
When Should You Buy Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...Analiz Makalesi • Aug 29
Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Shares Leap 28% Yet They're Still Not Telling The Full Story
Despite an already strong run, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have been powering on, with a...Analiz Makalesi • May 12
Tactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole Picture
The most recent earnings report from Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) was disappointing for...Analiz Makalesi • May 08
Slammed 28% Tactile Systems Technology, Inc. (NASDAQ:TCMD) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares are down a considerable...Analiz Makalesi • May 07
Why Tactile Systems Technology, Inc. (NASDAQ:TCMD) Could Be Worth Watching
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it received a lot of...Seeking Alpha • Apr 07
Tactile Systems Technology: Interesting Devices Company, Need More Clarity
Summary Tactile Systems produces medical devices for lymphedema and chronic venous insufficiency, with Flexitouch Plus being the flagship product and key revenue driver. The company's products are covered by major insurers, including Medicare and Veterans Administration, serving over 275 million Americans. Financially, TCMD has a market cap of $311mn, but faces risks from increasing competition, regulatory issues, and ongoing legal matters. Despite strong revenue streams, concerns about falling EBITDA and recent revenue misses warrant a cautious approach before making investment decisions. Read the full article on Seeking AlphaAnaliz Makalesi • Feb 23
Tactile Systems Technology (NASDAQ:TCMD) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analiz Makalesi • Nov 25
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 26%
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 26% gain in the...Analiz Makalesi • Nov 07
Tactile Systems Technology, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) came out with its third-quarter results last week, and we wanted to...
Yeni Anlatı • Sep 24
Nimbl Approval And Tech Investments Propel Growth Amid Shrinking Margins And Operational Risks
Investments in technology and workflow improvements, alongside FDA approval for Nimbl, indicate a strong focus on innovation and market expansion.Analiz Makalesi • Jul 17
Investors Holding Back On Tactile Systems Technology, Inc. (NASDAQ:TCMD)
With a price-to-sales (or "P/S") ratio of 1.1x Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) may be sending very...Analiz Makalesi • May 09
US$20.67: That's What Analysts Think Tactile Systems Technology, Inc. (NASDAQ:TCMD) Is Worth After Its Latest Results
Last week, you might have seen that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) released its quarterly result to...Analiz Makalesi • Feb 23
Tactile Systems Technology, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) filed its yearly result this time...Analiz Makalesi • Oct 10
Does Tactile Systems Technology (NASDAQ:TCMD) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Sep 16
Capital Allocation Trends At Tactile Systems Technology (NASDAQ:TCMD) Aren't Ideal
What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...Analiz Makalesi • Jul 13
Is It Time To Consider Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...Analiz Makalesi • May 10
Are Investors Undervaluing Tactile Systems Technology, Inc. (NASDAQ:TCMD) By 26%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Tactile Systems Technology fair value estimate is US$28.71...Analiz Makalesi • Feb 16
Is Tactile Systems Technology (NASDAQ:TCMD) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Hissedar Getirileri
| TCMD | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 13.7% | 3.9% | -2.6% |
| 1Y | 192.8% | -20.0% | 20.0% |
Getiri vs. Endüstri: TCMD geçen yıl % -20 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: TCMD geçen yıl % 20 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| TCMD volatility | |
|---|---|
| TCMD Average Weekly Movement | 6.3% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: TCMD son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: TCMD 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1995 | 1,086 | Sheri Dodd | tactilemedical.com |
Bir tıbbi teknoloji şirketi olan Tactile Systems Technology, Inc., Amerika Birleşik Devletleri'nde yetersiz hizmet alan kronik hastalıkları tedavi etmek için tıbbi cihazlar geliştirmekte ve sağlamaktadır. Lenfödem, flebolenfödem, lipödem, venöz yetmezlikler ve diğer ödem ve bacak ülseri türlerinin tedavisi için pnömatik bir kompresyon cihazı olan Flexitouch Plus sistemini; lenfödem, kronik ödem, venöz yetmezlik ve kronik yaraların evde tedavisi için pnömatik bir kompresyon cihazı olan Entre Plus Sistemini sunmaktadır. Şirket ayrıca üst ekstremite lenfödeminin tedavisi için pnömatik bir kompresyon platformu olan Nimbl; hastaların lenfödem hakkında bilgi edinmelerine, semptomlarını ve tedavilerini takip etmelerine ve ilerlemelerini doktorlarıyla paylaşmalarına yardımcı olan bir mobil uygulama olan Kylee; ve bronşektazi, kistik fibroz ve çeşitli nöromüsküler bozukluklardan kaynaklanan pulmoner sekresyonları olan hastaları tedavi etmek için taşınabilir bir yüksek frekanslı göğüs duvarı osilasyon yeleği olan AffloVest'i de sunmaktadır.
Tactile Systems Technology, Inc. Temel Bilgiler Özeti
| TCMD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$631.58m |
| Kazançlar(TTM) | US$20.30m |
| Gelir(TTM) | US$343.52m |
33.7x
F/K Oranı2.0x
P/S OranıTCMD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| TCMD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$343.52m |
| Gelir Maliyeti | US$81.11m |
| Brüt Kâr | US$262.41m |
| Diğer Giderler | US$242.12m |
| Kazançlar | US$20.30m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.90 |
| Brüt Marj | 76.39% |
| Net Kâr Marjı | 5.91% |
| Borç/Özkaynak Oranı | 0% |
TCMD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/26 18:14 |
| Gün Sonu Hisse Fiyatı | 2026/06/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Tactile Systems Technology, Inc. 12 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Argus Research Company |
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |